Also read Promise of COVID vaccines is 'phenomenal', WHO says“Scaling up a vaccine at this pace is unprecedented, and we have made significant progress as we have moved forward in the unknown," said spokeswoman Amy Rose.
In particular, she said, “scale up of the raw material supply chain took longer than expected."Modifications to the vaccine production lines in both the U.S.
and Europe are now complete, Rose said.“Finished doses are being made at a rapid pace," said Rose. “We are confident in our ability to supply 1.3 billion doses by the end of 2021."Earlier, the Wall Street Journal reported that supply-chain problems caused the New York-based drugmaker to reduce the number of vaccines it expects to ship worldwide this year.